📉 The Financial Deep Dive
Shukra Pharmaceuticals Limited has delivered a striking financial performance for the third quarter of FY26, showcasing remarkable top-line and bottom-line growth. Revenue from operations jumped an impressive 270.2% year-on-year (YoY) to ₹3,913.48 Lakhs, a substantial leap from ₹1,058.43 Lakhs in Q3 FY25. Quarter-on-quarter (QoQ), the company saw an even more significant surge of 565.7%. For the nine-month period ended December 31, 2025 (9M FY26), revenue grew 160.9% YoY to ₹5,040.33 Lakhs.
Profitability metrics followed suit with exceptional gains. Profit Before Tax (PBT) soared 555.4% YoY to ₹2,683.15 Lakhs in Q3 FY26. QoQ, PBT experienced an extraordinary surge of 13424.6%. For 9M FY26, PBT grew 391.7% YoY to ₹2,840.54 Lakhs. Net Profit also demonstrated robust growth, rising 386.2% YoY to ₹2,036.46 Lakhs in Q3 FY26, and 148.3% YoY for 9M FY26 to ₹2,377.46 Lakhs.
The Quality: A key highlight is the significant expansion in the Profit Before Tax (PBT) margin, which climbed to 67.17% in Q3 FY26 from 35.33% in Q3 FY25. This margin improvement appears to be driven by substantial cost efficiencies, particularly a reduction in the cost of materials consumed as a percentage of revenue, along with lower employee and other operating expenses. However, a notable point is the decline in basic EPS to ₹0.47 in Q3 FY26 from ₹0.72 in Q3 FY25 (a 34.7% YoY decrease), and ₹0.54 for 9M FY26 from ₹0.96 in 9M FY25 (a 43.75% YoY decrease). The company attributes this YoY decline in EPS to an increase in its paid-up equity share capital during the period.
The Grill: The company announcement provided no forward-looking statements, management guidance, or details on growth drivers and risks. Furthermore, balance sheet and cash flow statements were not included, limiting a complete financial assessment. The re-appointment of Mr. Dakshesh Shah as Managing Director for another five years was also noted.